Predictions
Organigram Holdings Inc.
Start price
Target price
Perf. (%)
€10.48
08.02.21
08.02.21
€14.00
08.02.22
08.02.22
-53.66%
28.01.22
28.01.22
Organigram Holdings Inc.
Start price
Target price
Perf. (%)
€5.88
25.01.21
25.01.21
€16.00
25.01.22
25.01.22
-15.72%
26.01.22
26.01.22
Aurinia Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€16.62
14.01.22
14.01.22
-
14.01.23
14.01.23
-12.67%
22.01.22
22.01.22
Could be worthwhile Investment >10% per year
Oncolytics Biotech
Start price
Target price
Perf. (%)
€2.42
18.04.21
18.04.21
€4.00
18.04.22
18.04.22
-33.47%
20.12.21
20.12.21
Xenon Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€14.20
18.09.21
18.09.21
€40.00
31.12.23
31.12.23
61.97%
16.12.21
16.12.21
Could be very worthwhile Investment >20% year
Aptose Biosciences
Start price
Target price
Perf. (%)
€3.22
11.06.21
11.06.21
€4.00
11.06.22
11.06.22
-69.57%
14.12.21
14.12.21
Could be worthwhile Investment >10% per year
Fennec Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€4.22
29.11.21
29.11.21
-
29.11.22
29.11.22
-16.11%
12.12.21
12.12.21
Could be worthwhile Investment >10% per year
InMed Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€39.25
30.11.21
30.11.21
-
30.11.22
30.11.22
-17.83%
12.12.21
12.12.21
Probably not worthwhile Investment
Organigram Holdings Inc.
Start price
Target price
Perf. (%)
€10.93
22.02.21
22.02.21
€100.00
22.02.22
22.02.22
-36.55%
12.12.21
12.12.21
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€3.91
01.12.21
01.12.21
-
01.12.22
01.12.22
-1.46%
11.12.21
11.12.21
Aurinia Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€17.00
28.11.21
28.11.21
-
28.11.22
28.11.22
7.65%
11.12.21
11.12.21
Could be worthwhile Investment >10% per year
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€3.96
01.12.21
01.12.21
€6.00
01.12.22
01.12.22
-2.70%
11.12.21
11.12.21
Could be worthwhile Investment >10% per year
Innovative
Good culture
Below average Management
Xenon Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€26.00
05.10.21
05.10.21
-
05.10.22
05.10.22
-10.00%
08.12.21
08.12.21
Probably not worthwhile Investment
Fennec Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€7.45
29.11.21
29.11.21
-
29.11.22
29.11.22
-50.07%
06.12.21
06.12.21
Risky Investment
Promis Neurosciences Inc.
Start price
Target price
Perf. (%)
€6.93
01.11.21
01.11.21
€10.80
01.11.22
01.11.22
-21.90%
05.12.21
05.12.21
ROE lower than 10% per year
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Organigram Holdings Inc.
Start price
Target price
Perf. (%)
€7.40
19.11.21
19.11.21
-
19.11.25
19.11.25
1.84%
29.11.21
29.11.21
Aurinia Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€17.50
22.11.21
22.11.21
-
22.11.22
22.11.22
-2.83%
28.11.21
28.11.21
Risky Investment
Aurinia Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€21.37
22.11.21
22.11.21
-
22.11.22
22.11.22
-20.45%
27.11.21
27.11.21
InMed Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€37.75
17.11.21
17.11.21
€50.00
17.11.22
17.11.22
4.64%
27.11.21
27.11.21
Could be worthwhile Investment >10% per year
Capable Management
Good culture
Little innovation
Aurinia Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€23.97
15.11.21
15.11.21
-
15.11.22
15.11.22
-28.16%
26.11.21
26.11.21
Could be worthwhile Investment >10% per year
Organigram Holdings Inc.
Start price
Target price
Perf. (%)
€8.04
14.11.21
14.11.21
-
14.11.22
14.11.22
-9.27%
26.11.21
26.11.21
Growpros Cannabis Ventures Inc
Start price
Target price
Perf. (%)
€0.13
19.11.21
19.11.21
-
19.11.25
19.11.25
2.54%
22.11.21
22.11.21
InMed Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€46.25
17.11.21
17.11.21
€37.50
30.11.22
30.11.22
-19.46%
18.11.21
18.11.21
Could be very worthwhile Investment >20% year
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€3.45
16.11.20
16.11.20
-
16.11.21
16.11.21
-14.81%
17.11.21
17.11.21
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Stable Large shareholder and/or long term investor
Future proof or reliable business model